Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Wins FDA Approval For Its First Meningitis Vaccine As ACIP Is Set To Meet

This article was originally published in The Pink Sheet Daily

Executive Summary

The vaccine targets four serotypes, but not the strain that causes the most cases among infants and toddlers, which is the most lucrative market.

You may also be interested in...



Consumer Group Seeks FTC Investigation Of Sanofi, Merck Vaccine Discounts To Physician Groups

Citizens for Responsibility and Ethics in Washington say Sanofi and Merck contracts require all physicians not to purchase competitors' vaccines in order for their group to get a discount.

Consumer Group Seeks FTC Investigation Of Sanofi, Merck Vaccine Discounts To Physician Groups

Citizens for Responsibility and Ethics in Washington say Sanofi and Merck contracts require all physicians not to purchase competitors' vaccines in order for their group to get a discount.

FDA Letter On Menveo News Release Offers Cautions On Launch Of Expanded Indication

Issued at almost the same time as Novartis submitted an sBLA for vaccination of younger children, FDA's advertising citation criticizes the pacing of an audio news release.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel